Back

Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes

2025-12-23 endocrinology Title + abstract only
View on medRxiv
Show abstract

Aims/hypothesisImmunotherapies such as Teplizumab can preserve residual beta cell function in individuals with newly diagnosed type 1 diabetes (T1D), but treatment response is variable. Currently, no biomarker exists to identify individuals most likely to benefit from immunotherapy. We believe that baseline serum metabolomic profiles can distinguish individuals who respond to treatment from nonresponders and predict therapeutic response. MethodsBaseline serum samples from 41 individuals newly d...

Predicted journal destinations